NasdaqGM - Delayed Quote USD

Ocular Therapeutix, Inc. (OCUL)

4.7450 +0.5450 (+12.98%)
At close: April 26 at 4:00 PM EDT
4.8600 +0.12 (+2.42%)
After hours: April 26 at 7:58 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
58,443.0000
58,443.0000
51,494.0000
43,522.0000
17,403.0000
Cost of Revenue
5,281.0000
5,281.0000
4,540.0000
4,406.0000
2,083.0000
Gross Profit
53,162.0000
53,162.0000
46,954.0000
39,116.0000
15,320.0000
Operating Expense
135,544.0000
135,544.0000
125,608.0000
117,153.0000
78,167.0000
Operating Income
-82,382.0000
-82,382.0000
-78,654.0000
-78,037.0000
-62,847.0000
Net Non Operating Interest Income Expense
-7,355.0000
-7,355.0000
-6,224.0000
-6,638.0000
-6,600.0000
Other Income Expense
9,001.0000
9,001.0000
13,840.0000
78,122.0000
-86,189.0000
Pretax Income
-80,736.0000
-80,736.0000
-71,038.0000
-6,553.0000
-155,636.0000
Net Income Common Stockholders
-80,736.0000
-80,736.0000
-71,038.0000
-6,553.0000
-155,636.0000
Average Dilution Earnings
-6,233.0000
-6,233.0000
-9,245.0000
-73,712.0000
--
Diluted NI Available to Com Stockholders
-86,969.0000
-86,969.0000
-80,283.0000
-80,265.0000
-155,636.0000
Basic EPS
-1.01
--
-0.92
-0.09
-2.56
Diluted EPS
-1.02
--
-0.97
-0.98
-2.56
Basic Average Shares
79,827.3620
--
76,875.0350
76,392.8700
60,752.2250
Diluted Average Shares
85,596.5940
--
82,644.2670
82,162.1020
60,752.2250
Total Operating Income as Reported
-82,382.0000
-82,382.0000
-78,654.0000
-78,037.0000
-62,847.0000
Total Expenses
140,825.0000
140,825.0000
130,148.0000
121,559.0000
80,250.0000
Net Income from Continuing & Discontinued Operation
-80,736.0000
-80,736.0000
-71,038.0000
-6,553.0000
-155,636.0000
Normalized Income
-89,738.0000
-89,738.0000
-84,879.0000
-84,674.0000
-69,447.0000
Interest Income
3,983.0000
3,983.0000
798.0000
33.0000
168.0000
Interest Expense
11,338.0000
11,338.0000
7,022.0000
6,671.0000
6,768.0000
Net Interest Income
-7,355.0000
-7,355.0000
-6,224.0000
-6,638.0000
-6,600.0000
EBIT
-69,398.0000
-69,398.0000
-64,016.0000
118.0000
-148,868.0000
EBITDA
-66,415.0000
-66,415.0000
-61,907.0000
2,539.0000
-146,095.0000
Reconciled Cost of Revenue
5,281.0000
5,281.0000
4,540.0000
4,406.0000
2,083.0000
Reconciled Depreciation
2,983.0000
2,983.0000
2,109.0000
2,421.0000
2,773.0000
Net Income from Continuing Operation Net Minority Interest
-80,736.0000
-80,736.0000
-71,038.0000
-6,553.0000
-155,636.0000
Total Unusual Items Excluding Goodwill
9,002.0000
9,002.0000
13,841.0000
78,121.0000
-86,189.0000
Total Unusual Items
9,002.0000
9,002.0000
13,841.0000
78,121.0000
-86,189.0000
Normalized EBITDA
-75,417.0000
-75,417.0000
-75,748.0000
-75,582.0000
-59,906.0000
12/31/2020 - 7/25/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EYPT EyePoint Pharmaceuticals, Inc.
16.75
+3.65%
 
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
 
XFOR X4 Pharmaceuticals, Inc.
1.1650
+3.10%
 
ABEO Abeona Therapeutics Inc.
3.2600
+2.19%
 
LPTX Leap Therapeutics, Inc.
3.2500
+2.52%
 
CYTK Cytokinetics, Incorporated
65.34
+0.83%
 
PDSB PDS Biotechnology Corporation
3.2700
+0.31%
 
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
 
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%
 
VINC Vincerx Pharma, Inc.
0.7300
-18.59%